FDA-TRACK: Over-The-Counter Monograph Drug User Fee Program Historical Performance - Meeting Management

Subscribe to FDA-TRACK Updates

Menu

OTC Monograph Order Request Submissions

Procedural Notifications and Responses

Meeting
Management

• • Current Performance
• • Historical Performance
• • Goals Summary

• • Current Performance
• • Historical Performance
• • Goals Summary

• • Current Performance
• • Historical Performance
• • Goals Summary

Relevant Links:

1. • OMUFA II Commitment Letter - FY 2026 to FY 2030
2. • OMUFA I Commitment Letter - FY 2021 to FY 2025
3. • OMUFA Performance Goals and Procedures
4. • Over-The-Counter Monograph Drug User Fee Program
5. • Coronavirus Aid, Relief, and Economic Security Act
6. • FDA-TRACK: OMUFA Performance Reports

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (Pub. L. 116-136) was signed into law.  In addition to aiding the COVID-19 response efforts, the CARES Act amended the FD&C Act to include statutory provisions that (1) reform and modernize the way over-the-counter (OTC) monograph drug products are regulated in the United States and (2) authorize the U.S. Food and Drug Administration (FDA or Agency) to assess and collect user fees from qualifying manufacturers of OTC monograph drug products and submitters of OTC monograph order requests.

Download OMUFA Historical Performance: Meeting Management Dataset

---

Footnotes:

• * FY 2025 and FY 2026 include preliminary performance as of 3/31/2026.
• ** Excludes meeting request submissions that were denied because of nonpayment of OMUFA user fees or meeting requests that were withdrawn prior to the meetings granted/denied response goal date.